Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study - Wockel, Achim; Brucker, Cosima; Decker, Thomas; Falbrede, Jorg; Forstbauer, Helmut; Gohler, Thomas; Hoffmann, Oliver; Jackisch, Christian; Janssen, Jan; Kohler, Andreas; Ludtke-Heckenkamp, Kerstin; Luftner, Diana; et al. (CANCER RESEARCH, 2021)
CRIS-Team WoS Importer:2021-03-26